Introduction
Gene therapy has provided an alternative treatment strategy for various inherited and acquired diseases. [1] [2] [3] Placental disorders and functional deficiencies cause significant fetal and maternal morbidity. [4] [5] [6] Pregnancies complicated by pre-eclampsia or by fetal growth restriction usually have defective maternal vascular responses to placentation. 7, 8 On the other hand, placental pathologic processes may be reversible and amenable to treatments as shown by the resolution of fetal hydrops after spontaneous infarction of placental chorionangioma. 9 Gene therapy could be used to improve utero-placental perfusion and functional status of utero-placental arteries. In severe pre-eclampsia a temporary expression of potentially useful genes, such as nitric oxide synthase or placental growth factor, could prolong the disease-free of 25 fetuses were analyzed for the presence of transgene at the time of death. In most fetuses expression of the LacZ gene was below the sensitivity of the X-gal staining, but expression was detected by PCR in 50%, 50% and 42% of the analyzed fetuses after adenoviral, plasmid/PEI and plasmid/liposome gene transfer, respectively. No major inflammatory changes were present in the transfected placentas as analyzed by general histology and macrophageand T cell-specific immunostainings. We conclude that catheter-mediated intravascular gene transfer with adenoviruses can be used for the transfection of placental trophoplastic cells, but plasmid complexes are inefficient for this purpose. However, selective angiographically guided gene transfer also led to leakage of the vector to fetuses. Therefore, if gene therapy is developed for the treatment of placental disorders, the gene-vector combination should not be harmful to the fetus and the expression of the transgene should only occur in placenta. Gene Therapy (2001) 8, 784-788.
period before delivery in early gestation and reduce the likelihood of long-term complications. However, very little information is available about the feasibility of placental gene transfer, route of delivery, target cells and leakage of vector with subsequent gene transfer to fetal tissues. [10] [11] [12] The current study was undertaken to evaluate the possibility of transfecting placenta with adenoviral vectors, plasmid/liposomes and plasmid/PEI complexes using a direct catheter-mediated delivery to uterine arteries under angiographic control. It was found that efficient gene transfer occurred in placental trophoplastic cells with the adenoviral vector. Plasmid/PEI and plasmid/liposome complexes were not efficient in transfecting placental trophoblastic cells, but transfected fetal membranes. Leakage of the vector with subsequent gene transfer to fetal tissues was indicative of the possible danger of unwanted side-effects. 
Results
Gene transfer to placenta was achieved by selective catheter-mediated injection into uterine arteries ( Figure 1 , Table 1 ). LacZ adenovirus vector resulted in 34 ± 10% gene transfer efficiency in the placenta 3 days after the gene transfer. Representative examples of the X-gal stainings are shown in Figure 2 . Intense nuclear X-gal staining was observed in trophoplastic cells (Figure 2a-d) . However, some variation in the intraplacental distribution of the transgene was detected (Figure 2d , e) depending on the localization of the placenta in the bicornic uterus. Very little, if any, transfection was seen in fetal membranes.
Plasmid/PEI and plasmid/liposome complexes led to a very low (Ͻ0.01%) transfection efficiency in trophoblastic cells (Figure 2f, g ). However, both plasmid/PEI and plasmid/liposome complexes transfected the basal plate of the placenta and fetal membranes more effectively than the adenovirus vector (Figure 2k, l) . Plasmid/ liposomes were equally well tolerated as adenoviruses, Gene Therapy but plasmid/PEI-complexes seemed to be toxic causing miscarriages when injected into the uterine arteries since the number of fetuses was clearly lower in the plasmid/PEI group than in the other groups (Table 1) . Transplacental passage and leakage of the vector with subsequent gene transfer to fetal tissues was analyzed by RT-PCR and X-gal stainings. Twenty-five fetuses were used for the analysis. Leakage of the vector was detected in all study groups (Table 1 ). In the adenovirus group, ␤-galactosidase-positive cells could be seen in two fetuses, one having ␤-galactosidase activity in a few cells in the umbilical cord and the other one in the mucosal cells of the intestine (Figure 3 ). In RT-PCR, leakage of the adenovirus was detected in 7 of the 14 fetuses ( Figure 3 , Table 1 ). In the plasmid/PEI group one fetus had X-galpositive cells in several tissues and two fetuses were positive for the ␤-galactosidase expression in RT-PCR. In the plasmid/liposome group, three of the seven fetuses were positive for the ␤-galactosidase expression in RT-PCR.
As additional controls, transfection efficiency after peripheral intravenous injection of the same gene transfer vectors to rabbit ear veins was studied. Adenovirus (n = 2) and plasmid complexes (n = 2) caused only sporadic transfection in placentas and no transfection was seen in the fetal tissues (data not shown).
Technically intravascular catheter-mediated gene transfer into the uterine arteries was well-tolerated and did not cause any tissue damage, such as placental infarcts. The anticipated reduction in uterine artery perfusion during the angiographic procedure was transient and administration of the vectors could be achieved via a minimally invasive angiographic procedure. Possible inflammatory reactions in the placenta were studied by immunostainings, which did not reveal any significant increases in the numbers of macrophages or T cells after the gene transfer. Because of the high transfection efficiency in the trophoplastic cells with the adenovirus vector, we examined adenovirus receptor expression in samples from human placenta. Intense immunostaining for Coxsackie adenovirus receptor (CAR) was found in the syncytial trophoplastic cells (Figure 2h ). Unfortunately, rabbit placentas could not be studied because the anti-human CAR antibody used did not react with rabbit tissues.
Systemic leakage of the gene transfer vectors was studied by sampling maternal liver, spleen and lungs. As expected, RT-PCR analysis revealed the expression of the transgene in all examined tissues (Figure 3e ). The results are similar to those reported earlier after intravascular gene transfer to rabbit aorta. 13 
Discussion
Feasibility and efficacy of angiographically guided direct utero-placental gene transfer was evaluated in the current study. Our results demonstrate that placental trophoblastic cells can be efficiently transfected with adenoviruses when delivered directly into uterine arteries. Plasmid/ PEI and plasmid/liposome complexes were not efficient in transfecting placental trophoblastic cells, but seemed to transfect fetal membranes and basal plate more efficiently than adenoviruses. Adenoviruses and plasmid/liposome complexes were equally well tolerated when injected into the uterine arteries. Plasmid/PEI complex injections to uterine arteries, on the other hand, were associated with miscarriages.
Figure 3 Biodistribution of gene transfer vector after placental gene transfer via uterine arteries. (a) X-gal staining of a rabbit doe liver showing expression of ␤-galactosidase in liver parenchyma after adenovirus mediated gene transfer. (b) Fetal liver from a doe in (a) showing no detectable transgene activity. (c) Umbilical cord showing two positive nucleae after adenovirus-mediated gene transfer. (d) Fetal lung showing a positive cell after plasmid/PEI gene transfer. (e) RT-PCR-analysis of various
All reporter gene assays were performed 3 days after the gene transfer. The observed adenoviral gene transfer efficiency in placenta was much higher (34% ± 10%) than that reported from most other tissues, such as arterial wall where up to 5% ± 1% of the cells can be transfected with the same adenovirus vector.
14 One explanation for this finding is the high level of CAR in syncytial trophoblastic cells in placenta.
It is obvious that the leakage of the vector to fetal tissues may constitute a serious safety problem in placental gene transfer. Feto-placental leakage was observed with all three gene transfer systems. In most fetuses the expression of the transgene was below the detection limit of the X-gal staining, but the transgene expression was detected by RT-PCR. Although plasmid and adenovirusmediated gene transfers do not alter genomic DNA, the leakage across the placenta indicates that the potential risk of fetal transfection cannot be avoided. Systemic leakage of the vector with subsequent gene transfer to maternal tissues was similar to that reported previously after systemic administration. 13 Only a few studies have been reported about the prospects of placental gene transfer. Senut and co-workers 10 injected genetically modified cells to rat placenta and achieved measurable levels of secreted gene products in fetal circulation. Xing and co-workers 11 used maternal systemic delivery or direct intraplacental needle injection of adenoviruses and demonstrated the possibility of transfecting rat placenta without altering the fetal genome. Intraplacental injection yielded a higher transduction efficiency than maternal systemic administration.
11 However, there is a serious concern that the direct intraplacental needle injection results in breakdown of the fetomaternal barrier, as clinically shown by elevated maternal serum alpha-fetoprotein levels caused by amniocentesis or chorion villus sampling. 15 Hence, the major advantage of the selective catheter-mediated gene transfer into the uterine arteries is that the physical fetomaternal barrier is not disrupted.
Transfection efficiency of adenovirus vector in placenta was higher than that in most other tissue studied previously. 2, 14, 16, 17 The observed transfection efficiency would probably be sufficient for therapeutic purposes, but the leakage of the vector to maternal tissues and across the placenta indicate that the safety of the procedure is still undefined. Furthermore, the leak across the placenta in clinical toxemia and fetal growth restriction with compromised placental functions may be different from that seen in the healthy placenta. Therefore, any intended therapeutic gene should be put under the control of the placenta-specific promoter. Also, gene vector/carrier combination should be safe and harmless to the fetus.
Materials and methods

Adenovirus and plasmid vectors
Human clinical grade vectors were used for the study. A nuclear targeted LacZ adenovirus (Ad5 serotype; E1−, partial E3-deletion) was cloned using homologous recombination of pAdenogal plasmid. 13 Replication-deficient adenoviruses were produced in 293 cells. Viruses were amplified using three separate rounds of plaque lysis and purified and concentrated by two rounds of ultracentrifugation. Titer assay, Southern blotting, E1/E2-selective PCR and cytopathic effect assay on A549 cells were used for the characterization of the virus.
14 A nuclear targeted LacZ plasmid was produced in E. coli and purified by the Qiagen method (Hilden, Germany). Both LacZ adenovirus and LacZ plasmid contained a CMV promoter. Polyethyleneimine (25 kDa; Sigma, St Louis, MO, USA) was used as a carrier for the LacZ-plasmid with a charge ratio of +4. 18 Lipofectin, a 1:1 (wt/wt) liposome formulation of cationic lipid N-[1-(2,3,-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA) and DOPE (1 mg/ml) was purhased from Gibco/BRL (Gaithersburg, MD, USA).
Gene Therapy
Animal model Pregnant New Zealand White rabbit does (4.0-6.5 kg) with planned pregnancies were obtained from the Finnish National Experimental Animal Center on day 5 of gestation. The animals were housed in individual cages. Rabbits were anesthetized with ketamine (Ketalar; ParkeDavis) (10 mg/kg i.m. and i.v.) and promazinum hydrocloridium (Hibernal; Rhone-Poulenc Rorer) (0.5 mg/kg i.m and i.v.) and used for the experiments between 14 and 28 gestational days. Halothane was used during the catheterization. Gene transfer was done via the right carotid artery through a 4 Fr introducer sheath (Cordis, Roden, The Netherlands). Under fluoroscopical control a 4 Fr diagnostic catheter was positioned into the orifice of the uterine artery. In some cases selective catheterization of the uterine arteries was done with a 2.1 or 3.0 Fr microcatheter (Tracker-18; Target Therapeutics, Fremont, CA, USA). A total of 1.0 × 10 10 p.f.u. of adenovirus, 250 g plasmid/PEI-25 complex or 500 g plasmid/DOTMA:DOPE liposome (1:2) was used in the final volume of 2.5 ml. The total volume of 2.5 ml limited the plasmid dose in the plasmid/PEI complex. The injection was done into both uterine arteries. Rabbits were killed 3 days after the gene transfer. Maternal and fetal tissues were collected via maternal laparotomy. All studies were approved by Experimental Animal Committee of the University of Kuopio, Finland.
Histology
After death, the transfected placentas were removed, flushed gently with saline and divided into three equal parts. The first part was snap frozen in liquid nitrogen and stored at −70°C. The next part was immersion-fixed in 4% paraformaldehyde/15% sucrose (pH 7.4) for 4 h, rinsed in 15% sucrose (pH 7.4) overnight and embedded in paraffin. The third part was immersion-fixed in 4% paraformaldehyde/phosphate buffered saline (PBS) (pH 7.4) for 30 min, rinsed 2 h in PBS, embedded in OCT compound (Miles) and stored at −70°C.
19 Paraffin sections were used for standard histology and immunocytochemical detection of macrophages (RAM-11; DAKO, dilution 1:50) and T cells (MCA-815; DAKO, dilution 1:100). Fresh human placenta samples were obtained from Cesarean sections from Kuopio University Hospital. Coxsackie adenovirus receptor (CAR) immunostaining was done as described. 20 Histology was analyzed using Image-Pro Plus software with Olympus AX70 microscope (Olympus Optical, Tokyo, Japan).
Gene transfer efficiency
Evaluation of the gene transfer efficiency was done using X-gal staining of OCT embedded tissue sections.
14 Gene transfer efficiency was calculated as a percentage of the ␤-galactosidase-positive nuclei relative to the total number of nuclei in eight randomly selected X-gal-stained sections of the trophoblastic area. 16 Results are presented as mean ± s.d.
RT-PCR
Total RNA was extracted from tissues using Trizol Reagent (Gibco-BRL, Rockville, MD, USA) according to the manufacturers' instructions and 2 g of RNA was used for cDNA synthesis.
14 Primers for LacZ were designed to distinguish between endogenous and transduced genes by selecting the 5Ј-primers from the CMV promoter and the 3Ј-primers from the coding region.
14 Amplification of the LacZ was done in a 50 l PCR mixture containing: 20 pmol of the upper primer (5Ј-TTGGAGGCCTAGGCTTTTGC-3Ј), 20 pmol of the lower primer (5Ј-ATACTGTCGT CGTCCCCTCA-3Ј ), 1.5 mm MgCl 2 , 0.2 mm dNTPs, 2% deionized formamide and 1 × buffer. The conditions for the first PCR cycle were: +96°C 4 min for denaturation and +80°C 3 min during which the DNA polymerase (Finnzymes, Espoo, Finland) was added. This was followed by 30 cycles each consisting of +94°C for 45 s for denaturation, +58°C for 45 s for primer annealing, and +72°C for 50 s for extension with the final extension of 5 min at +72°C. Four l of the first PCR product was used for the second nested PCR. 13 PCR reactions were carried out in a 50 l reaction mixture containing 20 pmol of the upper primer (5Ј-GGTAGAA GACCCCAAGGACTTT-3Ј), 20 pmol of the lower primer (5Ј-CGCC ATTCGCCATTCAG-3Ј) and 1.5 mm MgCl 2 . The conditions for the first PCR cycle were: +96°C for 3 min and +80°C for 3 min. This was followed by 32 cycles each consisting of +94°C for 60 s, +58°C for 15 s, +72°C for 90 s with the final extension of 5 min at +72°C. PCR products were visualized in agarose gel using ethidium bromide staining.
